Medicilon appoints Dr. Lilly Xu as the new head of technology!

Medicilon appoints Dr. Lilly Xu as the new head of technology!

Medicilon, a leader in preclinical research, has appointed Dr. Lilly Xu appointed as new technical director. With more than 30 years of experience in drug development, Dr. Xu will play a critical role in driving Medicilon's technological advancements and expanding the company's global presence. Her impressive career includes positions at renowned companies such as Pharmaron, Icagen, Purdue Pharma, Sanofi and Amgen, highlighting her extensive knowledge of pharmacokinetics, toxicology and drug metabolism apa-ots.at reported.

In her new role, Dr. Xu will support Medicilon's leadership team in developing innovative solutions, strengthening the company's capabilities. “We are very pleased to welcome Dr. Xu at this pivotal stage in Medicilon’s growth,” said Dr. Chunlin Chen, the company's founder and managing director. Dr. For her part, Xu expressed her excitement about the new challenge: “I am honored to become part of Medicilon's forward-looking team,” she emphasized, adding that she aims to transform research results into clinical breakthroughs.

New technologies and global expansion

Medicilon aims to further expand its technological platforms, including nucleic acids, antibody-drug conjugates (ADCs), and cell and gene therapies. This expansion is designed to solidify Medicilon's position as a pioneer in preclinical drug development. Investors Hangout informed about this that with Dr. Xu's extensive knowledge and global perspective, strategic steps can now be taken to enormously strengthen the company's innovative strength.

With the appointment of Dr. Xu emphasizes Medicilon's ambition to remain at the top in a highly competitive environment. It will not only promote technological innovation but also optimize the drug development process to provide effective solutions to customers.